SG11201811709WA - Compounds, compositions, and methods for the treatment of disease - Google Patents
Compounds, compositions, and methods for the treatment of diseaseInfo
- Publication number
- SG11201811709WA SG11201811709WA SG11201811709WA SG11201811709WA SG11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA SG 11201811709W A SG11201811709W A SG 11201811709WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- shrewsbury
- july
- compositions
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 241000286209 Phasianidae Species 0.000 abstract 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 abstract 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 abstract 1
- 241000218645 Cedrus Species 0.000 abstract 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 abstract 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 abstract 1
- 241000218657 Picea Species 0.000 abstract 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000007863 pattern recognition receptors Human genes 0.000 abstract 1
- 108010089193 pattern recognition receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 January 2018 (11.01.2018) WI P0 I PC T IiiimmomiolollmonoloololionolioommomovoimIE (10) International Publication Number WO 2018/009648 Al 00 71 O - LI- (51) International Patent Classification: A61K 31/7052 (2006.01) A61K 39/12 (2006.01) A61K 31/7084 (2006.01) (21) International Application Number: PCT/US2017/040882 (22) International Filing Date: 06 July 2017 (06.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/359,039 06 July 2016 (06.07.2016) US 62/363,118 15 July 2016 (15.07.2016) US 62/403,530 03 October 2016 (03.10.2016) US 62/411,424 21 October 2016 (21.10.2016) US 62/444,141 09 January 2017 (09.01.2017) US 62/462,679 23 February 2017 (23.02.2017) US 62/470,746 13 March 2017 (13.03.2017) US 62/508,846 19 May 2017 (19.05.2017) US (71) Applicant: SPEROVIE BIOSCIENCES, INC. [US/US]; 113 Cedar Street, Milford, MA 01757 (US). (72) Inventors: IYER, Radhakrishnan, P.; 15 Quail Hollow Drive, Shrewsbury, MA 01545 (US). SHERI, Anjaneyu- lu; 12 Pheasant Hill Drive, Shrewsbury, MA 01545 (US). PADMANABHAN, Seetharamaiyer; 67 Fottler Avenue, Lexington, MA 02420 (US). MEHER, Geeta; 4 Capital Road #1, Milford, MA 01757 (US). ZHOU, Shenghua; 21 Stoney Hill Road, Shrewsbury, MA 01545 (US). CHAL- LA, Sreerupa; 3132 Arbor Dr., Shrewsbury, MA 01545 (US). GIMI, Rayomand, H.; 41 Stonegate Road, Chelms- ford, MA 01824 (US). CLEARY, Dillon; 99 Spruce Street, Middleborough, MA 02346 (US). (74) Agent: GORDON, Dana, M. et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) (54) Title: COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE 10000 cn 'too 10 1 T ▪ ern iss ue c Cr, ...I- ix, ▪ co co co o CV CO CM CO P.- 0 0 0 CV Cr) ..er L0 CON-CO 0 0 CV CO \"V- CI_ C.1 CV CV CV CV CV CV CV CV CV CI CI Cr, Cr> EEEEEEEEEco_to-co_co_co_co_ C=L CL CL 0_ CL CL CL CL CL CL CL CL CL CL CL CLcD c)c..)c_3(_3(\"c_)c_3(_)c_)EeEEEEEEEEEEEEEEEEEEEEEEEc_a C-D C_D C_D CD C_D C-3 C-1. C-3 C-3 C-3 C-D c-3 c-D c-3 C.D C.D C-D C-D -ro FIG. 1A 25µM Compound O O (57) : Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811709WA true SG11201811709WA (en) | 2019-01-30 |
Family
ID=60913147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811709WA SG11201811709WA (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (en) |
| EP (1) | EP3481402A4 (en) |
| JP (3) | JP7100227B2 (en) |
| KR (1) | KR102569881B1 (en) |
| CN (1) | CN109843302B (en) |
| AU (1) | AU2017293781B2 (en) |
| CA (1) | CA3029644A1 (en) |
| IL (1) | IL264049B2 (en) |
| MX (2) | MX2019000216A (en) |
| SG (1) | SG11201811709WA (en) |
| TW (1) | TWI689514B (en) |
| WO (1) | WO2018009648A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102530488B1 (en) | 2016-03-18 | 2023-05-08 | 이뮨 센서, 엘엘씨 | Cyclic di-nucleotide compounds and methods of use |
| KR102569881B1 (en) * | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | Compounds, compositions and methods for treating disease |
| JOP20170192A1 (en) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | Cyclic dinucleotide |
| CA3058134A1 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| AR113224A1 (en) | 2017-04-28 | 2020-02-19 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A STING AGONIST |
| US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| CN111566120B (en) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
| TWI833744B (en) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-cyclic dinucleotides |
| TW202005654A (en) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2'2'-cyclic dinucleotides |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US20210309692A1 (en) * | 2018-07-10 | 2021-10-07 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (en) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | Cyclic dinucleotides as sting agonists |
| KR102567590B1 (en) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | Novel cyclic dinucleotide derivatives and their antibody drug conjugates |
| MX2021003207A (en) | 2018-09-21 | 2021-06-23 | Shanghai De Novo Pharmatech Co Ltd | Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application. |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| WO2020092617A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| JP7224688B2 (en) * | 2019-01-10 | 2023-02-20 | 南▲開▼大学 | Cyclic dinucleotide prodrug molecules, methods of making and uses thereof |
| DK3934757T3 (en) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-CYCLIC DINUCLEOTIDES AND THEIR PRODUCTS |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| AU2020267486A1 (en) | 2019-05-09 | 2021-11-11 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as STING modulators |
| EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| BR112022015283A2 (en) | 2020-03-06 | 2022-09-20 | Daiichi Sankyo Co Ltd | ANTIBODY-DRUG CONJUGATE INCLUDING CYCLIC DINUCLEOTIDE DERIVATIVES |
| WO2021206158A1 (en) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Method of cancer therapy |
| CN111909223A (en) * | 2020-07-17 | 2020-11-10 | 清华大学 | Cyclic dinucleotide covalent modifier and preparation method and application thereof |
| US20230256109A1 (en) | 2020-08-07 | 2023-08-17 | Tambo, Inc. | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy |
| JPWO2022050300A1 (en) | 2020-09-02 | 2022-03-10 | ||
| CA3197167A1 (en) | 2020-11-09 | 2022-05-12 | He Xu | Antibody drug conjugates |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| WO2005087238A2 (en) * | 2004-03-15 | 2005-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EP2448954A1 (en) * | 2009-07-01 | 2012-05-09 | Rutgers, The State University of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (en) * | 2010-03-26 | 2013-12-18 | 北京大学 | C-di-GMP, analogues thereof and preparation method thereof |
| KR20150022996A (en) | 2012-06-08 | 2015-03-04 | 아두로 바이오테크 | Compositions and methods for cancer immunotherapy |
| EA201590396A1 (en) * | 2012-12-13 | 2015-12-30 | Адуро Биотек, Инк. | COMPOSITION CONTAINING CYCLIC PURINE DYNUCLEOTIDES WITH A SPECIFIC STEREHEMISTRY, AND THE METHOD OF ITS PREPARATION AND APPLICATION |
| CA2895175C (en) * | 2012-12-19 | 2021-06-01 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| EP2935616B1 (en) * | 2012-12-20 | 2018-02-28 | Hill's Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| JP6153116B2 (en) * | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | Triazole-linked cyclic dinucleotide analogs |
| CA2840937A1 (en) | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Vaccine composition for transdermal administration |
| US20140329889A1 (en) * | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| PT2996473T (en) * | 2013-05-18 | 2019-11-18 | Univ California | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN103864910B (en) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | The shellfish pattern recognition receptors LRRP of a kind of novel specific combination LPS |
| EP3116542A2 (en) | 2014-03-12 | 2017-01-18 | Yeda Research and Development Co., Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| CA2950033A1 (en) | 2014-06-04 | 2015-12-10 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| CN107148424B (en) * | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | Cyclic dinucleotides for inducing cytokines |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3268035A4 (en) * | 2015-03-10 | 2018-10-31 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| UA123701C2 (en) | 2015-08-13 | 2021-05-19 | Мерк Шарп І Доум Корп. | Cyclic di-nucleotide compounds as sting agonists |
| US10906930B2 (en) | 2015-10-28 | 2021-02-02 | Chinook Therapeutics, Inc. | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling |
| ES2863225T3 (en) * | 2015-12-03 | 2021-10-11 | Glaxosmithkline Ip Dev Ltd | Purine cyclic dinucleotides as modulators of sting |
| CN106540260A (en) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | Interferon gene stimulatory protein(SP)（STING）Application of the agonist in anti-alzheimer's disease |
| WO2017106740A1 (en) | 2015-12-16 | 2017-06-22 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production |
| EP3402801A1 (en) | 2016-01-11 | 2018-11-21 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| CA3016457A1 (en) | 2016-03-02 | 2017-09-08 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| KR102569881B1 (en) * | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | Compounds, compositions and methods for treating disease |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| PL3523287T3 (en) | 2016-10-04 | 2021-12-20 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| JOP20170192A1 (en) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | Cyclic dinucleotide |
| EP3558358A4 (en) | 2016-12-20 | 2020-09-30 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| WO2018118665A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| WO2018156625A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| UY37695A (en) | 2017-04-28 | 2018-11-30 | Novartis Ag | BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| TWI799426B (en) | 2017-06-22 | 2023-04-21 | 英商克拉德夫製藥有限公司 | Small molecule modulators of human sting |
| EP3642197A1 (en) | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| WO2018234805A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
| US11707531B2 (en) * | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
-
2017
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/en active IP Right Grant
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en unknown
- 2017-07-06 IL IL264049A patent/IL264049B2/en unknown
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
- 2017-07-06 MX MX2019000216A patent/MX2019000216A/en unknown
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/en active Active
- 2017-07-06 TW TW106122757A patent/TWI689514B/en active
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/en active Active
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/en unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/en active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP2023182645A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3481402A4 (en) | 2020-01-22 |
| CA3029644A1 (en) | 2018-01-11 |
| IL264049A (en) | 2019-01-31 |
| US20220054523A1 (en) | 2022-02-24 |
| JP2022106989A (en) | 2022-07-20 |
| JP2019532084A (en) | 2019-11-07 |
| JP7100227B2 (en) | 2022-07-13 |
| AU2017293781A1 (en) | 2019-02-07 |
| WO2018009648A1 (en) | 2018-01-11 |
| TWI689514B (en) | 2020-04-01 |
| JP2023182645A (en) | 2023-12-26 |
| US11033569B2 (en) | 2021-06-15 |
| TW201805295A (en) | 2018-02-16 |
| IL264049B1 (en) | 2023-07-01 |
| MX2022006260A (en) | 2022-06-29 |
| US20190262372A1 (en) | 2019-08-29 |
| IL264049B2 (en) | 2023-11-01 |
| CN109843302A (en) | 2019-06-04 |
| KR20190032408A (en) | 2019-03-27 |
| US11744845B2 (en) | 2023-09-05 |
| AU2017293781B2 (en) | 2022-12-22 |
| CN109843302B (en) | 2022-11-29 |
| EP3481402A1 (en) | 2019-05-15 |
| KR102569881B1 (en) | 2023-08-22 |
| MX2019000216A (en) | 2019-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811709WA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201900154VA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201909003YA (en) | Integrated vascular access device and anchor pad | |
| SG11201909561RA (en) | Octree-based convolutional neural network | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201903202VA (en) | Osmotic membrane | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201909107YA (en) | Stenosis treatment | |
| SG11201810192TA (en) | Antibacterial compositions | |
| SG11201906807VA (en) | Compositions and methods for promoting hair growth with mpc1 inhibitors | |
| SG11201908513RA (en) | Peptides for treatment of diabetes |